先端巨大症・巨人症の世界市場:疫学予測

◆英語タイトル:Acromegaly and Gigantism- Epidemiology Forecast To 2023
◆商品コード:DLVE704028
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2017年4月
◆ページ数:51
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,750 ⇒換算¥291,500見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD5,500 ⇒換算¥583,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD8,250 ⇒換算¥874,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s“Acromegaly and Gigantism- Epidemiology Forecast to 2023” Report provides an overview of the epidemiology trends of Acromegaly in seven major markets (US, France, Germany, Italy, Spain, UK and Japan) and Gigantism in six major markets (US, United Kingdom, France, Germany, Italy and Spain). It includes 10 years epidemiology historical and forecasted data of prevalent cases of Acromegaly and Gigantism by age, sex and sub populations. The Report also discusses the prevailing risk factors, disease burden with special emphasis.
Acromegaly is a rare but serious hormonal disorder caused by excessive growth hormone (GH) in the blood in adults. Acromegaly in adults occurs mainly in middle-aged men and women. In This condition, the bones increase in size, including those of the hands, feet and face. Acromegaly is uncommon and physical changes occur gradually thus the condition often isn’t recognized immediately and if not treated promptly, it can lead to serious illness and even become life-threatening. According to DelveInsight’s estimates, the prevalent cases of Acromegaly in the 7 MM are expected to increase with a CAGR of 0.72% for the forecast period i.e., 2013-2023.
Gigantism is excessive production of GH in children which is extremely rare and leads to exaggerated bone growth and an abnormal increase in height. It results from high linear growth due to excessive action of insulin like growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the growth plate cartilage fuses in adulthood. According to DelveInsight’s estimates, prevalent cases of Gigantism in the 6 MM are expected to increase with a CAGR of 2% and Acromegaly in the 7 MM are expected to increase with a CAGR of 0.72% for the forecast period i.e., 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Key Coverage and Benefits:

The report will help in developing business strategies by understanding the trends shaping and driving the global epidemiology of Acromegaly and Gigantism.
Identifying prevalent patient populations as well as risk factors in the global Acromegaly and Gigantism market will help to improve product design, pricing, and launch plans.

【レポートの目次】

Report Introduction
Acromegaly and Gigantism: Overview
Causes
Signs and Symptoms
Risk Factors
Pathophysiology
Diagnosis
Treatment
Epidemiology of Acromegaly in 7MM
Epidemiology and Patient Population
Assumptions and Caveats
Prevalent Population of Acromegaly in 7MM
United States
Sex Specific Prevalence of Acromegaly in United States
Age- Specific Prevalence of Acromegaly in United States
Europe
United Kingdom
Sex Specific Prevalence of Acromegaly in United Kingdom
Age- Specific Prevalence of Acromegaly in United Kingdom
France
Sex Specific Prevalence of Acromegaly in France
Age- Specific Prevalence of Acromegaly in France
Italy
Sex Specific Prevalence of Acromegaly in Italy
Age- Specific Prevalence of Acromegaly in Italy
Spain
Sex Specific Prevalence of Acromegaly in Spain
Age- Specific Prevalence of Acromegaly in Spain
Germany
Sex Specific Prevalence of Acromegaly in Germany
Age- Specific Prevalence of Acromegaly in Germany
Japan
Sex Specific Prevalence of Acromegaly in Japan
Age- Specific Prevalence of Acromegaly in Japan
Epidemiology of Gigantism in 6MM
Epidemiology and Patient Population
Prevalent Population of Gigantism in 6MM
United States
Europe
United Kingdom
France
Italy
Spain
Germany
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

Table 1: Prevalent Population of Acromegaly in 7MM (2013-2023)
Table 2: Prevalent Population of Acromegaly in United States (2013-2023)
Table 3: Sex Specific Prevalence of Acromegaly in United States (2013-2023)
Table 4: Age-Specific Prevalence of Acromegaly in United States (2013-2023)
Table 5: Prevalent Population of Acromegaly in United Kingdom (2013-2023)
Table 6: Sex Specific Prevalence of Acromegaly in United Kingdom (2013-2023)
Table 7: Age-Specific Prevalence of Acromegaly in United Kingdom (2013-2023)
Table 8: Prevalent Population of Acromegaly in France (2013-2023)
Table 9: Sex Specific Prevalence of Acromegaly in France (2013-2023)
Table 10: Age-Specific Prevalence of Acromegaly in France (2013-2023)
Table 11: Prevalent Population of Acromegaly in Italy (2013-2023)
Table 12: Sex Specific Prevalence of Acromegaly in Italy (2013-2023)
Table 13: Age-Specific Prevalence of Acromegaly in Italy (2013-2023)
Table 14: Prevalent Population of Acromegaly in Spain (2013-2023)
Table 15: Sex Specific Prevalence of Acromegaly in Spain (2013-2023)
Table 16: Age-Specific Prevalence of Acromegaly in Spain (2013-2023)
Table 17: Prevalent Population of Acromegaly in Germany (2013-2023)
Table 18: Sex Specific Prevalence of Acromegaly in Germany (2013-2023)
Table 19:Age-Specific Prevalence of Acromegaly in Germany (2013-2023)
Table 20: Prevalent Population of Acromegaly in Japan (2013-2023)
Table 21: Sex Specific Prevalence of Acromegaly in Japan (2013-2023)
Table 22:Age-Specific Prevalence of Acromegaly in Japan (2013-2023)
Table 23: Prevalent Population of Gigantism in 6MM (2013-2023)
Table 24: Prevalent Population of Gigantism in United States (2013-2023)
Table 25: Prevalent Population of Gigantism in United Kingdom (2013-2023)
Table 26: Prevalent Population of Gigantism in France (2013-2023)
Table 27: Prevalent Population of Gigantism in Italy (2013-2023)
Table 28: Prevalent Population of Gigantism in Spain (2013-2023)
Table 29: Prevalent Population of Gigantism in Germany (2013-2023)


Figure 1: The pathway involved in Growth hormone production and how it affects the target tissues
Figure 2: Prevalent Population of Acromegaly in 7MM (2013-2023)
Figure 3: Prevalent Population of Acromegaly in United States (2013-2023)
Figure 4: Sex Specific Prevalence of Acromegaly in United States (2013-2023)
Figure 5: Age-Specific Prevalence of Acromegaly in United States (2013-2023)
Figure 6: Prevalent Population of Acromegaly in United Kingdom (2013-2023)
Figure 7: Sex Specific Prevalence of Acromegaly in United Kingdom (2013-2023)
Figure 8: Age-Specific Prevalence of Acromegaly in United Kingdom (2013-2023)
Figure 9: Prevalent Population of Acromegaly in France (2013-2023)
Figure 10: Sex Specific Prevalence of Acromegaly in France (2013-2023)
Figure 11: Age-Specific Prevalence of Acromegaly in France (2013-2023)
Figure 12: Prevalent Population of Acromegaly in Italy (2013-2023)
Figure 13: Sex Specific Prevalence of Acromegaly in Italy (2013-2023)
Figure 14: Age-Specific Prevalence of Acromegaly in Italy (2013-2023)
Figure 15: Prevalent Population of Acromegaly in Spain (2013-2023)
Figure 16: Sex Specific Prevalence of Acromegaly in Spain (2013-2023)
Figure 17: Age-Specific Prevalence of Acromegaly in Spain (2013-2023)
Figure 18: Prevalent Population of Acromegaly in Germany (2013-2023)
Figure 19: Sex Specific Prevalence of Acromegaly in Germany (2013-2023)
Figure 20:Age-Specific Prevalence of Acromegaly in Germany (2013-2023)
Figure 21: Prevalent Population of Acromegaly in Japan (2013-2023)
Figure 22: Sex Specific Prevalence of Acromegaly in Japan (2013-2023)
Figure 23:Age-Specific Prevalence of Acromegaly in Japan (2013-2023)
Figure 24: Prevalent Population of Gigantism in 6MM (2013-2023)
Figure 25: Prevalent Population of Gigantism in United States (2013-2023)
Figure 26: Prevalent Population of Gigantism in United Kingdom (2013-2023)
Figure 27: Prevalent Population of Gigantism in France (2013-2023)
Figure 28: Prevalent Population of Gigantism in Italy (2013-2023)
Figure 29: Prevalent Population of Gigantism in Spain (2013-2023)
Figure 30:Prevalent Population of Gigantism in Germany (2013-2023)


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 先端巨大症・巨人症の世界市場:疫学予測(Acromegaly and Gigantism- Epidemiology Forecast To 2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆